226 related articles for article (PubMed ID: 17704746)
1. Serum levels of sFas and sFasL during chemotherapy of lung cancer.
Naumnik W; Izycki T; Ossolinska M; Chyczewska E
Exp Oncol; 2007 Jun; 29(2):132-6. PubMed ID: 17704746
[TBL] [Abstract][Full Text] [Related]
2. Serum levels of interleukin-18 (IL-18) and soluble interleukin-2 receptor (sIL-2R) in lung cancer.
Naumnik W; Chyczewska E; Kovalchuk O; Tałałaj J; Izycki T; Panek B
Rocz Akad Med Bialymst; 2004; 49():246-51. PubMed ID: 15631351
[TBL] [Abstract][Full Text] [Related]
3. Serum levels of IGF-I and IGF-II in patients with lung cancer during chemotherapy.
Izycki T; Chyczewska E; Naumnik W; Talalaj J; Panek B; Ossolinska M
Exp Oncol; 2004 Dec; 26(4):316-9. PubMed ID: 15627066
[TBL] [Abstract][Full Text] [Related]
4. The evaluation of soluble Fas and soluble Fas ligand levels of bronchoalveolar lavage fluid in lung cancer patients.
Erdoğan B; Uzaslan E; Budak F; Karadağ M; Ediger D; Oral B; Göral G; Ege E; Gözü O
Tuberk Toraks; 2005; 53(2):127-31. PubMed ID: 16100648
[TBL] [Abstract][Full Text] [Related]
5. Serum soluble Fas (CD95) and Fas ligand profiles in chronic kidney failure.
Perianayagam MC; Murray SL; Balakrishnan VS; Guo D; King AJ; Pereira BJ; Jaber BL
J Lab Clin Med; 2000 Oct; 136(4):320-7. PubMed ID: 11039853
[TBL] [Abstract][Full Text] [Related]
6. Serum levels of VEGF-C, VEGF-D, and sVEGF-R2 in patients with lung cancer during chemotherapy.
Naumnik W; Izycki T; Swidzińska E; Ossolińiska M; Chyczewska E
Oncol Res; 2007; 16(9):445-51. PubMed ID: 18074680
[TBL] [Abstract][Full Text] [Related]
7. Serum endostatin levels in patients with lung carcinoma.
Swidzińska E; Ossolińska M; Naumnik W; Trojan S; Chyczewska E
Rocz Akad Med Bialymst; 2005; 50():197-200. PubMed ID: 16358965
[TBL] [Abstract][Full Text] [Related]
8. Analysis of cytotoxic T lymphocytes and Fas/FasL in Japanese patients with non-small cell lung cancer associated with HLA-A2.
Yoshimura C; Nomura S; Kanazawa S; Kuwana M; Muramatsu M; Yamaguchi K; Fukuhara S
J Cancer Res Clin Oncol; 2002 Nov; 128(11):581-8. PubMed ID: 12458337
[TBL] [Abstract][Full Text] [Related]
9. Soluble Fas and Fas ligand provide new information on metastasis and response to chemotherapy in SCLC patients.
Shimizu M; Kondo M; Ito Y; Kume H; Suzuki R; Yamaki K
Cancer Detect Prev; 2005; 29(2):175-80. PubMed ID: 15829378
[TBL] [Abstract][Full Text] [Related]
10. Soluble Fas receptor and soluble Fas ligand in the serum of women with uterine tumors.
Kondera-Anasz Z; Mielczarek-Palacz A; Sikora J
Apoptosis; 2005 Oct; 10(5):1143-9. PubMed ID: 16151647
[TBL] [Abstract][Full Text] [Related]
11. Prognostic significance of soluble Fas in the serum of patients with bladder cancer.
Mizutani Y; Yoshida O; Bonavida B
J Urol; 1998 Aug; 160(2):571-6. PubMed ID: 9679930
[TBL] [Abstract][Full Text] [Related]
12. Prognostic significance of soluble fas and soluble fas ligand in serum of patients with complete hydatidiform moles.
Soni S; Rath G; Deval R; Salhan S; Mishra AK; Saxena S
Am J Reprod Immunol; 2011 Sep; 66(3):230-6. PubMed ID: 21385271
[TBL] [Abstract][Full Text] [Related]
13. Serum and follicular fluid levels of soluble Fas, soluble Fas ligand and apoptosis of luteinized granulosa cells in PCOS patients undergoing IVF.
Onalan G; Selam B; Baran Y; Cincik M; Onalan R; Gündüz U; Ural AU; Pabuccu R
Hum Reprod; 2005 Sep; 20(9):2391-5. PubMed ID: 15932917
[TBL] [Abstract][Full Text] [Related]
14. Soluble Fas (sFas) and soluble Fas ligand (sFas-L) balance in laryngeal carcinoma before and after surgical treatment.
Pignataro L; Arisi E; Sambataro G; Corsi MM
J Surg Oncol; 2003 Jun; 83(2):112-5. PubMed ID: 12772205
[TBL] [Abstract][Full Text] [Related]
15. Soluble form of TRAIL, Fas and FasL in the serum of patients with B-CLL.
Jabłońska E; Kiersnowska-Rogowska B; Rogowski F; Parfieńczyk A; Puzewska W; Bukin M
Rocz Akad Med Bialymst; 2005; 50():204-7. PubMed ID: 16358967
[TBL] [Abstract][Full Text] [Related]
16. Serum DNase I, soluble Fas/FasL levels and cell surface Fas expression in patients with SLE: a possible explanation for the lack of efficacy of hrDNase I treatment.
Tinazzi E; Puccetti A; Gerli R; Rigo A; Migliorini P; Simeoni S; Beri R; Dolcino M; Martinelli N; Corrocher R; Lunardi C
Int Immunol; 2009 Mar; 21(3):237-43. PubMed ID: 19181929
[TBL] [Abstract][Full Text] [Related]
17. Variations in the serum concentrations of soluble Fas and soluble Fas ligand in Vietnamese patients infected with hepatitis B virus.
Song le H; Binh VQ; Duy DN; Bock TC; Kremsner PG; Luty AJ; Mavoungou E
J Med Virol; 2004 Jun; 73(2):244-9. PubMed ID: 15122799
[TBL] [Abstract][Full Text] [Related]
18. Circulating soluble Fas concentration in breast cancer patients.
Ueno T; Toi M; Tominaga T
Clin Cancer Res; 1999 Nov; 5(11):3529-33. PubMed ID: 10589768
[TBL] [Abstract][Full Text] [Related]
19. Serum soluble fas level as a prognostic factor in patients with gynecological malignancies.
Konno R; Takano T; Sato S; Yajima A
Clin Cancer Res; 2000 Sep; 6(9):3576-80. PubMed ID: 10999747
[TBL] [Abstract][Full Text] [Related]
20. sFas levels increase in response to cisplatin-based chemotherapy in lung cancer patients.
Ulukaya E; Acilan C; Yilmaz M; Yilmaztepe-Oral A; Ari F; Zik B; Ursavas A; Tokullugil AH
Cell Biochem Funct; 2010 Oct; 28(7):565-70. PubMed ID: 20941746
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
